CB1 receptor density and CB1 receptor-mediated functional effects in rat hippocampus are decreased by an intracerebroventricularly administered antisense oligodeoxynucleotide

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 360, Issue 4, 1999, Pages 421-427

  Kathmann, M ^a   Bauer, U ^a   Schlicker, E ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

35S GTP S binding studies; Acetylcholine release; Antisense oligodeoxynucleotides; Cannabinoid receptors 3H SR141716 binding studies; CB(1); I.c.v. administration; Rat hippocampus and striatum

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CANNABINOID RECEPTOR; ACETYLCHOLINE; DRUG RECEPTOR; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; RIMONABANT;

ACETYLCHOLINE RELEASE; ANIMAL EXPERIMENT; ARTICLE; DRUG RECEPTOR BINDING; HIPPOCAMPUS; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; RAT; RECEPTOR DENSITY; ANIMAL; BRAIN CORTEX; CLASSIFICATION; DRUG EFFECT; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; METABOLISM; PROTEIN BINDING; RADIOASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECRETION; VISUAL CORTEX; WISTAR RAT;

ACETYLCHOLINE; ANIMALS; CEREBRAL CORTEX; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HIPPOCAMPUS; INJECTIONS, INTRAVENTRICULAR; MALE; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PIPERIDINES; PROTEIN BINDING; PYRAZOLES; RADIOLIGAND ASSAY; RATS; RATS, WISTAR; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VISUAL CORTEX;

EID: 0032590232     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002109900091     Document Type: Article

References (27)

1. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254
2. Branch AD (1998) A good antisense molecule is hard to find. Trends Biochem Sci 23:45-50
3. 35S]GTPγS binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity. J Biol Chem 273:16865-16873
4. Childers SR, Breivogel CS (1998) Cannabis and endogenous cannabinoid systems. Drug Alcohol Depend 51:173-187
5. Crooke ST (1992) Therapeutic applications of oligonucleotides. Annu Rev Pharmacol Toxicol 32:329-376
6. Davidkova G, Weiss B (1998) Pharmacological inhibition of dopaminergic and other neurotransmitter receptors using antisense oligodeoxynucleotides. In: Crooke ST (eds) Antisense research and application. Springer, Berlin Heidelberg New York, pp 263-308
7. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949
8. Edsall SA, Knapp RJ, Vanderah TW, Roeske WR, Consroe P, Yamamura HI (1996) Antisense oligodeoxynucleotide treatment to the brain cannabinoid receptor inhibits antinociception. Neuroreport 7:593-596
9. Gifford AN, Ashby CR (1996) Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55,212-2, and is potentiated by the cannabinoid antagonist, SR141716A. J Pharmacol Exp Ther 277:1431-1436
10. Gifford AN, Samiian L, Gatley SJ, Ashby CR (1997) Examination of the effect of the cannabinoid receptor agonist CP 55,940, on the electrically evoked transmitter release from rat brain slices. Eur J Pharmacol 324:187-192
11. Hunter SA, Burstein SH (1997) Receptor mediation in cannabinoid stimulated arachidonic mobilization and anandamide synthesis. Life Sci 60:1563-1573
12. Hunter AJ, Leslie RA, Gloger IS, Lawrence M (1995) Probing the function of novel genes in the nervous system: is antisense the answer? Trends Neurosci 18:329-331
13. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561-564
14. Matthies H, Schroeder H, Wagner M, Hoellt V, Krug M (1995) NMDA/R1-antisense oligonucleotide influences the early stage of long-term potentiation in the CA1-region of rat hippocampus. Neurosci Lett 202:113-116
15. Mechoulam R, Hanus L, Martin B (1994) Search for endogenous ligands of the cannabinoid receptor. Biochem Pharmacol 48:1537-1544
16. Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61-65
17. Paxinos G, Watson C (1997) The rat brain in stereotaxic coordinates. 3rd edn. Academic, New York
18. 2 receptors. Pharmacol Ther 74:129-180
19. Richardson JD, Aanonsen L, Hargreaves KM (1998) Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia. J Neurosci 18:451-457
20. Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C, Martinez S, Maurani J, Néliat G, Caput D, Ferrara P, Soubrié P, Brelière JC, Le Fur G (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240-244
21. 1, cannabinoid receptor antagonist, in rodent brain. Life Sci 58:1239-1247
22. 2 cannabinoid receptor. J Pharmacol Exp Ther 284:644-650
23. 1 receptor-mediated inhibition of noradrenaline release in the human and guinea-pig hippocampus. Naunyn-Schmiedeberg's Arch Pharmacol 356:583-589
24. Stella N, Schweitzer P, Piomelli D (1997) A second endogenous cannabinoid that modulates long-term potentiation. Nature 388:773-778
25. Wahlestedt C, Golanov E, Yamamoto S, Yee F, Ericson H, Yoo H, Inturrisi CE, Reis DJ (1993a) Antisense oligodeoxynucleotide to NMDA-R1 receptor channel protect cortical neurons from excitotoxicity and reduce focal ischaemic infarctions. Nature 363:260-263
26. Wahlestedt C, Pich EM, Koob GF, Yee F, Heilig M (1993b) Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science 259:528-531
27. Zhang SP, Zhou LW, Morabito M, Lin RCS, Weiss B (1996) Uptake and distribution of fluorescein-labelled D2 dopamine receptor antisense oligodeoxynucleotide in mouse brain. J Mol Neurosci 7:13-28